Proteomic Discovery of Diabetic Nephropathy Biomarkers

Advances in Chronic Kidney Disease

Volumn 17, Issue 6, 2010, Pages 480-486

  Merchant, Michael L ^a,b   Klein, Jon B ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Peptidome; Plasma; Proteome; Serum; Targeted proteomics; Urine

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGEN; CYSTATIN C; FAS ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INOSITOL PENTAKISPHOSPHATE 2 KINASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEOME; TENASCIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; ZONA OCCLUDENS 3;

AGE; DIABETIC NEPHROPATHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SERUM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; URINE;

AGE FACTORS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PEPTIDES; PROTEINS; PROTEINURIA; PROTEOMICS; RENAL INSUFFICIENCY;

EID: 78049426170     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.09.001     Document Type: Review

References (36)

1. Merchant M.L., Klein J.B. Proteomics and diabetic nephropathy. Semin Nephrol 2007, 27:627-636.
2. Issaq H., Veenstra T. Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE): Advances and perspectives. Biotechniques 2008, 44:697-698, 700.
3. Zhou M., Veenstra T. Mass spectrometry: m/z 1983-2008. Biotechniques 2008, 44:667-668, 670.
4. Matt P., Fu Z., Fu Q., et al. Biomarker discovery: Proteome fractionation and separation in biological samples. Physiol Genomics 2008, 33:12-17.
5. Qian W.J., Jacobs J.M., Liu T., et al. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics 2006, 5:1727-1744.
6. Chalkley R.J., Hansen K.C., Baldwin M.A. Bioinformatic methods to exploit mass spectrometric data for proteomic applications. Methods Enzymol 2005, 402:289-312.
7. Beck L.H., Bonegio R.G., Lambeau G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361:11-21.
8. Viberti G.C., Hill R.D., Jarrett R.J., et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982, 1:1430-1432.
9. Parving H.H., Oxenboll B., Svendsen P.A., et al. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh) 1982, 100:550-555.
10. Perkins B.A., Krolewski A.S. Early nephropathy in type 1 diabetes: A new perspective on who will and who will not progress. Curr Diab Rep 2005, 5:455-463.
11. Giorgino F., Laviola L., Cavallo Perin P., et al. Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: The EURODIAB Prospective Complications Study. Diabetologia 2004, 47:1020-1028.
12. Perkins B.A., Ficociello L.H., Silva K.H., et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348:2285-2293.
13. Araki S., Haneda M., Sugimoto T., et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005, 54:2983-2987.
14. Perkins B.A., Ficociello L.H., Ostrander B.E., et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007, 18:1353-1361.
15. Perkins B.A., Nelson R.G., Ostrander B.E., et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: Results of a 4-year follow-up study. J Am Soc Nephrol 2005, 16:1404-1412.
16. Julian B.A., Suzuki H., Suzuki Y., et al. Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease. Proteomics Clin Appl 2009, 3:1029-1043.
17. Powell D.W., Merchant M.L., Link A.J. Discovery of regulatory molecular events and biomarkers using 2D capillary chromatography and mass spectrometry. Expert Rev Proteomics 2006, 3:63-74.
18. Zurbig P., Decramer S., Dakna M., et al. The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics 2009, 9:2108-2117.
19. Rossing K., Mischak H., Dakna M., et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008, 19:1283-1290.
20. Baggerman G., Verleyen P., Clynen E., et al. Peptidomics. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 803:3-16.
21. Jurgens M., Appel A., Heine G., et al. Towards characterization of the human urinary peptidome. Comb Chem High Throughput Screen 2005, 8:757-765.
22. Villanueva J., Shaffer D.R., Philip J., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006, 116:271-284.
23. Merchant M.L., Perkins B.A., Boratyn G.M., et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009, 20:2065-2074.
24. Sharma K., Ramachandrarao S., Qiu G., et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008, 118:1645-1656.
25. Brehm M.A., Schenk T.M., Zhou X., et al. Intracellular localization of human inositol 1,3,4,5,6-pentakisphosphate 2-kinase. Biochem J 2007, 408:335-345.
26. Anderson P., Kedersha N. RNA granules. J Cell Biol 2006, 172:803-808.
27. Overgaard A.J., Hansen H.G., Lajer M., et al. Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. Proteome Sci 2010, 8:4.
28. Gilbert R.E., Cooper M.E. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?. Kidney Int 1999, 56:1627-1637.
29. Rivero A., Mora C., Muros M., et al. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci (Lond) 2009, 116:479-492.
30. Navarro-Gonzalez J.F., Jarque A., Muros M., et al. Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev 2009, 20:165-173.
31. Navarro-Gonzalez J.F., Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008, 19:433-442.
32. Wolkow P.P., Niewczas M.A., Perkins B., et al. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol 2008, 19:789-797.
33. Niewczas M.A., Ficociello L.H., Johnson A.C., et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009, 4:62-70.
34. Yang Y.H., Zhang S., Cui J.F., et al. Diagnostic potential of serum protein pattern in Type 2 diabetic nephropathy. Diabet Med 2007, 24:1386-1392.
35. Papale M., Di Paolo S., Magistroni R., et al. Urine proteome analysis may allow non-invasive differential diagnosis of diabetic nephropathy. Diabet Care 2010 Jul 29, [Epub ahead of print].
36. Afkarian M, Bhasin M, Dillon ST, et al: Optimizing a proteomics platform for urine biomarker discovery. Mol Cell Proteomics (in press).